New Fred Hutch spinoff to commercialize cord blood stem cell therapies based on work by Drs. Colleen Delaney, Irwin Bernstein
Dec. 3, 2015
| By Susan Keown / Fred Hutch News Service
A new Fred Hutch spinoff, Nohla Therapeutics, will commercialize cord blood stem cell therapies based on work by Dr. Colleen Delaney and Dr. Irwin Bernstein. In preliminary studies, the company’s first product helps stem cells engraft more quickly after transplant and protects patients from deadly infections during this vulnerable period.
Ex-patient’s wife recalls how her sacred mission to save her husband led her to Fred Hutch
Aug. 26, 2015
| By Bill Briggs / Fred Hutch News Service
After her husband, Hugh, was diagnosed with an aggressive form of leukemia, Aimee Fagan filled a notebook with doctors' names, study results, and this mantra: 'It's you and me against cancer, do you think it has a chance?'
An extraordinary girl contends with a rare, life-threatening blood disease — and undergoes a made-to-order clinical study in cord-blood transplantation
Jan. 5, 2015
| By Ellie Sheldon / Seattle Cancer Care Alliance
Since being diagnosed with aplastic anemia in 2009, Kyra Diaz, 11, has stood tall through a series of demanding medical treatments to arrest and, finally, cure her disease. Ultimately, in October 2013, she received a transplant of stem cells derived from umbilical cord blood developed by researchers at Fred Hutchinson Cancer Research Center that saved her life.